Lonza Announces Results of the 2026 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Source: EQS|
All Board members standing for re-election were re-elected, each for a further term in office until the completion of the AGM 2027. The following Board members stood for re-election: Shareholders approved the election of Claudia Süssmuth- Following the conclusion of the final terms of The shareholders supported all other motions proposed by the Board of Directors, including the approval of the Non-Financial Report, the Remuneration Report 2025 (consultative vote) and the compensation for the Board of Directors and the Executive Committee. A dividend of For further information please see the detailed voting results. About Lonza Lonza is the world’s largest contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across five continents, the global Lonza team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing. Lonza Contact Details
Additional Information and Disclaimer Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of All trademarks belong to Lonza, and are registered in the Privacy Policy link
End of Media Release |
| Language: | English |
| Company: | |
| Münchensteinerstrasse 38 | |
| 4052 |
|
| Phone: | +4161 316 81 11 |
| Internet: | www.lonza.com |
| ISIN: | CH0013841017 |
| Valor: | 1384101 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2324208 |
| End of News | |
|
|
2324208 08.05.2026 CET/CEST